NewAmsterdam Pharma (NAMS) announced the appointment of John Smither as an independent director to its Board of Directors. Smither will also serve as chair of NewAmsterdam Pharma’s Audit Committee. Most recently, Smither served as the Chief Financial Officer at Arcutis Biotherapeutics (ARQT), where he was responsible for all financial aspects of the company’s business, including leading Arcutis’ successful initial public offering and two capital raises.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on NAMS:
- NewAmsterdam Pharma Appoints John W. Smither to its Board of Directors
- NewAmsterdam announces results from obicetrapib /ezetimibe combo trial
- NewAmsterdam initiated with an Outperform at Credit Suisse
- Analysts Say These 2 Stocks Could Double Your Money — Here’s Why They Could Surge
- NewAmsterdam initiated with an Outperform at SVB Securities
